Bluetrum(SH:688332) Xin Lang Cai Jing·2025-09-22 02:55Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index has shown a 0.64% increase, with notable gains from stocks like Lingyun Optics (up 8.32%) and Lexin Technology (up 6.33%) [3] - The National Healthcare Security Administration has initiated the 11th round of centralized drug procurement, emphasizing a shift away from the "lowest bid wins" approach, which is expected to positively impact the pharmaceutical sector [4][6] - The semiconductor industry remains a key investment focus, driven by technological advancements, supportive policies, and strong capital interest [5] Electronic Sector - The National Internet Information Office has instructed major domestic tech companies to halt the procurement of NVIDIA's RTX Pro 6000D chips tailored for the Chinese market and to cancel existing orders [3] - OpenAI has partnered with domestic suppliers to produce future devices, with plans to launch its first device by late 2026 or early 2027 [3] - Domestic GPU manufacturer Moore Threads is set to hold its IPO on the Sci-Tech Innovation Board on September 26 [3] Pharmaceutical Sector - The new centralized procurement rules aim to break the "lowest bid wins" mentality, which is expected to alleviate valuation pressures in the pharmaceutical and biotech sectors [6] - The shift in competition logic towards "cost-performance ratio" and "innovation" is anticipated to highlight a trend of "de-involution" in the pharmaceutical sector, driving valuation recovery [6] ETF Insights - The Sci-Tech Innovation Board 100 Index ETF (588030) has seen a 1.85 billion yuan increase in scale over the past week, ranking second among comparable funds [6] - The ETF's recent net inflow was 32.6 million yuan, with a total of 247 million yuan net inflow over the last five trading days [7] - The top two sectors in the Sci-Tech 100 Index are electronics (37.51%) and pharmaceuticals (18.97%), indicating a diversified investment opportunity in the tech sector [6]